Diagnósticos da América : Dasa posted double-digit revenue and EBITDA growth in 2Q24, advancing a major hospital JV

About this update from Diagnosticos Da America S.a.

Dasa delivered strong 2Q24 results with 10% revenue and 27% EBITDA growth, reduced leverage, and a narrowed net loss. The Amil joint venture and R$1.5B capital injection position the company for further financial strengthening and operational scale.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Diagnosticos Da America S.a.